We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

6 hedge funds and large institutions have $18.2K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% less funds holding

Funds holding: 7 → 6 (-1)

30% less capital invested

Capital invested by funds: $26K → $18.2K (-$7.82K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AA
Ancora Advisors
Ohio
-$865
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$8.5K – – –
LDB
2
Lee, Danner & Bass
Tennessee
$4K – – –
AW
3
Atlas Wealth
Ohio
$2.25K – – –
LIA
4
LBMC Investment Advisors
Tennessee
$1.72K – – –
ACM
5
Academy Capital Management
Texas
$1.69K – – –
AA
6
Ancora Advisors
Ohio
– -$865 -7,650 Closed

PVCT Hedge Fund Activity: Q3 2023 in Review

6 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q3 2023, worth a combined $18.2K — down 30% from $26K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of PVCT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Ancora Advisors, exiting entirely with an estimated $865 sold.

  • 6 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q3 2023, down from 7 in Q2 2023.
  • Funds reported $18.2K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q3 2023, down 30% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q3 2023 and 1 closed out, a net change of -1 holder.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q3 2023 was Ancora Advisors, an estimated $865 sold.

Based on aggregated 13F filings for Q3 2023.